PD-L1 Testing, and Pembrolizumab, ' Changes Approach to Every Patient ' PD-L1 Testing, and Pembrolizumab, ' Changes Approach to Every Patient '
Pembrolizumab ' s remarkable impact means ' we now have to change our approach to every single patient with adenocarcinoma and squamous cell carcinoma, ' argues Mark Kris.Medscape Oncology
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news
More News: Adenocarcinoma | Cancer & Oncology | Carcinoma | Hematology | Skin Cancer | Squamous Cell Carcinoma